Page 417 - Williams Hematology ( PDFDrive )

392 Part V: Therapeutic Principles <CN>: <CT> PB

123. Aarts MJ, Peters FP, Mandigers CM, et al: Primary granulocyte colony-stimulating fac- Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann
tor prophylaxis during the first two cycles only or throughout all chemotherapy cycles Oncol 17:1051, 2006.
in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 31:4290, 2013. 140. Gerdemann U, Katari UL, Papadopoulou A, et al: Safety and clinical efficacy of rap-
124. Dranitsaris G, Rayson D, Vincent M, et al: Identifying patients at high risk for neutro- idly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV
penic complications during chemotherapy for metastatic breast cancer with doxoru- infections after allogeneic hematopoietic stem cell transplant. Mol Ther 21:2113, 2013.
bicin or pegylated liposomal doxorubicin: The development of a prediction model. Am 141. Chemaly RF, Ullmann AJ, Stoelben S, et al: Letermovir for cytomegalovirus prophylaxis
J Clin OncolJ Clin Oncol 31:369, 2008. in hematopoietic-cell transplantation. N Engl J Med 370:1781, 2014.
125. Aapro MS, Bohlius J, Cameron DA, et al: 2010 Update of EORTC guidelines for the 142. Marty FM, Winston DJ, Rowley SD, et al: CMX001 to prevent cytomegalovirus disease
use of granulocyte-colony stimulating factor to reduce the incidence of chemother- in hematopoietic-cell transplantation. N Engl J Med 369:1227, 2013.
apy-induced febrile neutropenia in adult patients with lymphoproliferative disorders 143. Curtis KK, Connolly MK, Northfelt DW: Live, attenuated varicella zoster vaccination of
and solid tumours. Eur J Cancer 47:8, 2011. an immunocompromised patient. J Gen Intern Med. 23:648, 2008.
126. Gardner A, Mattiuzzi G, Faderl S, et al: Randomized comparison of cooked and non- 144. Akan H, Antia VP, Kouba M, et al: Preventing invasive fungal disease in patients with
cooked diets in patients undergoing remission induction therapy for acute myeloid haematological malignancies and the recipients of haematopoietic stem cell transplan-
leukemia. J Clin Oncol 26:5684, 2008. tation: Practical aspects. J Antimicrob Chemother 68 (Suppl 3):iii5, 2013.
127. Russell JA, Poon MC, Jones AR, et al: Allogeneic bone-marrow transplantation without 145. Maschmeyer G: The changing face of febrile neutropenia-from monotherapy to moulds
protective isolation in adults with malignant disease. Lancet 339:38, 1992. to mucositis. Prevention of mould infections. J Antimicrob Chemother 63 (Suppl 1):i27,
128. Warkentin DI, Epstein JB, Campbell LM, et al: Valacyclovir versus acyclovir for HSV 2009.
prophylaxis in neutropenic patients. Ann Pharmacother 36:1525, 2002. 146. Michallet M, Ito JI: Approaches to the management of invasive fungal infections in
129. Boeckh M, Nichols WG: The impact of cytomegalovirus serostatus of donor and recip- hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 27:3398,
ient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis 2009.
and preemptive therapy. Blood 103:2003, 2004. 147. Goodman JL, Winston DJ, Greenfield RA, et al: A controlled trial of fluconazole to
130. Vickrey E, Allen S, Mehta J, Singhal S: Acyclovir to prevent reactivation of varicella prevent fungal infections in patients undergoing bone marrow transplantation. N Engl
zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. J Med 326:845, 1992.
Cancer 115:229, 2009. 148. Vehreschild JJ, Bohme A, Buchheidt D, et al: A double-blind trial on prophylactic vori-
131. Centers for Disease Control and Prevention (CDC): Updated recommendations for use conazole (VRC) or placebo during induction chemotherapy for acute myelogenous
of VariZIG—United States, 2013. MMWR Morb Mortal Wkly Rep 62:574, 2013. leukaemia (AML). J Infect 55:445, 2007.
132. Ljungman P: The role of cytomegalovirus serostatus on outcome of hematopoietic stem 149. Ping B, Zhu Y, Gao Y, et al: Second- versus first-generation azoles for antifungal pro-
cell transplantation. Curr Opin Hematol 21:466, 2014. phylaxis in hematology patients: A systematic review and meta-analysis. Ann Hematol
133. Ringden O, Erkers T, Aschan J, et al: A prospective randomized toxicity study to com- 92:831, 2013.
pare reduced-intensity and myeloablative conditioning in patients with myeloid leu- 150. Cornely OA, Maertens J, Winston DJ, et al: Posaconazole vs. fluconazole or itraconazole
kaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med prophylaxis in patients with neutropenia. N Engl J Med 356:348, 2007.
274:153, 2013. 151. Mattiuzzi GN, Alvarado G, Giles FJ, et al: Open-label, randomized comparison of itra-
134. Kekre N, Tokessy M, Mallick R, et al: Is cytomegalovirus testing of blood products still conazole versus caspofungin for prophylaxis in patients with hematologic malignan-
needed for hematopoietic stem cell transplant recipients in the era of universal leukore- cies. Antimicrob Agents Chemother 50:143, 2006.
duction? Biol Blood Marrow Transplant 19:1719, 2013. 152. van Burik JA, Ratanatharathorn V, Stepan DE, et al: Micafungin versus fluconazole for
135. van der Heiden PL, Kalpoe JS, Barge RM, et al: Oral valganciclovir as pre-emptive prophylaxis against invasive fungal infections during neutropenia in patients undergo-
therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407, 2004.
ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 153. Green H, Paul M, Vidal L, Leibovici L: Prophylaxis for Pneumocystis pneumonia
37:693, 2006. (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev
136. Ayala E, Greene J, Sandin R, et al: Valganciclovir is safe and effective as pre-emptive (3):CD005590, 2007.
therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone 154. Colby C, McAfee S, Sackstein R, et al: A prospective randomized trial comparing the
Marrow Transplant 37:851, 2006. toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis
137. Ar MC, Ozbalak M, Tuzuner N, et al: Severe bone marrow failure due to valganciclo- carinii pneumonia prophylaxis following autologous peripheral blood stem cell trans-
vir overdose after renal transplantation from cadaveric donors: Four consecutive cases. plantation. Bone Marrow Transplant 24:897, 1999.
Transplant Proc 41:1648, 2009. 155. Sangiolo D, Storer B, Nash R, et al: Toxicity and efficacy of daily dapsone as Pneumo-
138. Allice T, Busca A, Locatelli F, et al: Valganciclovir as pre-emptive therapy for cytomeg- cystis jiroveci prophylaxis after hematopoietic stem cell transplantation: A case-control
alovirus infection post-allogenic stem cell transplantation: Implications for the emer- study. Biol Blood Marrow Transplant 11:521, 2005.
gence of drug-resistant cytomegalovirus. J Antimicrob Chemother 63:600, 2009. 156. Appelbaum FR, Forman SJ, Negrin RS, Blume KG: Thomas’ Hematopoietic Cell Trans-
139. Sandherr M, Einsele H, Hebart H, et al: Antiviral prophylaxis in patients with haemato- plantation. Wiley-Blackwell, New York, 2009.
logical malignancies and solid tumours: Guidelines of the Infectious Diseases Working

Kaushansky_chapter 24_p0383-0392.indd 392 9/17/15 5:58 PM